Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro

Abstract

Background: Ethylenediamine tetra acetic acid (EDTA) is used in several biomedical applications. Aim: The aim of this study was to investigate the effect of EDTA treatment on anticancer efficacy of cisplatin (Cis) against human breast cancer (MCF-7) cells in vitro. Materials and Methods: MCF-7 cells were treated either with Cis, EDTA, or their combination for 24h in vitro. The percentages (%) of the inhibitory, and the median inhibitory concentration (IC50) of EDTA were determined by MTT assay. The % of Cis and EDTA on early and late apoptosis, necrosis, and cell cycle of MCF-7 were assessed by flow cytometry. Results: Our data showed slight antitumor effects for EDTA in vitro. However, Cis/EDTA treatment increased the antitumor efficacy of Cis as evidenced by increasing IC50, and the percentage of MCF-7 mortality. Cis/EDTA co-treatment also increased the % of apoptotic and necrotic MCF-7 cells post 24 h of treatment (26.57 and 16.28%, respectively). Furthermore, this co-treatment arrested MCF-7 cell cycle at G0 phase (32.8%) and G2/M phase (30.25%). Conclusion: Co-treatment of EDTA with Cis increased the anticancer efficacy of Cis.

Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice

“…In addition, it has been reported that EDTA might prevent iron from forming complex with DOX, which could prevent reactive oxygen species damaging (Duvillard et al, 2004). These results were in line with previous study reported that EDTA could enhance the antitumor efficacy of low dose of Cis in EAC-bearing mice by increasing the percentages of apoptotic tumor cells (El-Naggar et al, 2019;El-Naggar et al, 2022). Furthermore, previous study reported that the treatment with liposomes loaded with EDTA alone did not show any antitumor effects, however, liposomes loaded with EDTA and doxorubicin could significantly reduce drug toxicity without altering the antitumor activity (Song et al, 2014).…”